Anne-Marie Duliege, M.D., M.S., has over 20 years of scientific and clinical leadership experience in the pharmaceutical industry. At Affymax, Inc., Dr. Duliege, is Chief Medical Officer and as of 2012, also Head of Research and Clinical Development. Under Dr. Duliege’s leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product, OMONTYS®. She joined Affymax in 2004 as V.P. of clinical development and regulatory affairs, and was instrumental in raising capital and taking the company public. She is also an Adjunct Clinical Assistant Professor at the Lucile Packard Children’s Hospital. She serves on the board of CIRM, the California Institute for Regenerative Medicine (stem cell research) and on board of BayBIO.
Prior to joining Affymax, Dr. Duliege worked at Chiron Corporation and at Genentech, Inc.. In addition to M.D. degree, Dr. Duliege has an M.S. in Epidemiology and an M.S. in Biostatistics.